Scarica l'app Stockscreener
76.20
0.46%
-0.35
Tarsus Pharmaceuticals Inc Borsa (TARS) Ultime notizie
[144] Tarsus Pharmaceuticals, Inc. SEC Filing - Stock Titan
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Vanguard Group Inc. - MarketBeat
Tarsus Pharmaceuticals at TD Cowen Conference: Eyeing Blockbuster Growth By Investing.com - Investing.com Canada
TARS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
A Look At Tarsus Pharmaceuticals (TARS) Valuation After 2025 Results And New Shelf Registration - Sahm
Tarsus Pharmaceuticals (TARS) Stock Analysis: Strong Buy Ratings and 21.88% Upside Potential - DirectorsTalk Interviews
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Passes High-Growth Momentum and Minervini Trend Template Screen - ChartMill
Aug PreEarnings: Why is Oak Woods Acquisition Corporation Equity Right stock going upWeekly Trade Recap & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Artisan Partners Limited Partnership Boosts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
(TARS) Risk Channels and Responsive Allocation - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to Hold Rating by Zacks Research - MarketBeat
Stream Tarsus Pharma at TD Cowen and Barclays investor events in March - Stock Titan
HC Wainwright Brokers Decrease Earnings Estimates for TARS - MarketBeat
Tarsus Pharmaceuticals (TARS) Is Up 14.8% After XDEMVY-Fueled Revenue Surge and New Equity Shelf Filing - simplywall.st
Has The Market Rerated Tarsus Pharmaceuticals (TARS) Too Cautiously After XDEMVY Adoption Headlines? - Yahoo Finance
Tarsus Pharmaceuticals (TARS) Receives Analyst Rating Upgrade fr - GuruFocus
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $105.00 Price Target at Oppenheimer - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $90.00 at Guggenheim - MarketBeat
TARS: Guggenheim Raises Price Target to $90, Maintains Buy Ratin - GuruFocus
Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $105 From $95, Maintains Outperform Rating - marketscreener.com
Analysts Offer Predictions for TARS FY2030 Earnings - MarketBeat
Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Healthcare Innovator with 32.92% Potential Upside - DirectorsTalk Interviews
Tarsus Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - VisionMonday.com
Tarsus Pharmaceuticals (TARS) Narrowing EPS Loss Backs Bullish Earnings Turnaround Narrative - simplywall.st
Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential (NASDAQ:TARS) - Seeking Alpha
Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap UpTime to Buy? - MarketBeat
Tarsus Pharmaceuticals (TARS) Shares Surge Over 11% - GuruFocus
Tarsus Pharmaceuticals Q4 2025 Earnings Call Highlights - Intellectia AI
Tarsus Pharma's XDEMVY Sales Soar 150% In FY25, Peak Sales Potential To Exceed $2Bln - RTTNews
Tarsus Pharmaceuticals, Inc. (TARS) reports Q4 loss, beats revenue estimates - MSN
Decoding Tarsus Pharmaceuticals Inc (TARS): A Strategic SWOT Ins - GuruFocus
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates - Bitget
Tarsus Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
TARS: 2026 sales guidance set at $670–$700M, with XDEMVY on track for $2B+ US peak sales - TradingView
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Q4 2025 Earnings: Revenue Soars on XDEMVY Sales, But Losses Widen - ChartMill
Earnings call transcript: Tarsus Pharmaceuticals Q4 2025 sees robust growth By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: Tarsus Pharmaceuticals Q4 2025 sees robust growth - Investing.com
Tarsus Pharmaceuticals Adds David Pyott, Boosts Leadership with Allergan Experience - timothysykes.com
Tarsus Pharmaceuticals Q4 Loss Shrinks, Revenue Rise - marketscreener.com
Earnings Flash (TARS) Tarsus Pharmaceuticals Posts Q4 Loss $0.20, vs. Loss of $0.60 a Year Ago - marketscreener.com
Earnings Flash (TARS) Tarsus Pharmaceuticals, Inc. Reports Q4 Revenue $151.7M, vs. FactSet Est of $144.6M - marketscreener.com
Tarsus Pharmaceuticals Reports $451.4 Million in XDEMVY® Sales for Full-Year 2025 and Announces New Clinical Trials for Ocular Rosacea and Lyme Disease Prevention - Quiver Quantitative
Tarsus Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Insights into Tarsus Pharmaceuticals Q4 Earnings - Benzinga
BRIEF-Tarsus Pharmaceuticals Q4 EPS USD -0.2 - TradingView
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements - GlobeNewswire
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Will Tarsus Pharmaceuticals Inc. stock recover after earnings2025 Technical Patterns & Daily Growth Stock Investment Tips - mfd.ru
Published on: 2026-02-21 16:01:43 - baoquankhu1.vn
What is the long term forecast for Tarsus Pharmaceuticals Inc. stockBull Run & Smart Swing Trading Alerts - mfd.ru
Tarsus Pharmaceuticals to Report Q4 and Full Year 2025 Results - National Today
Earnings Preview: Tarsus Pharmaceuticals - Benzinga
Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q4 2025 Result - GuruFocus
Tarsus Pharmaceuticals Appoints David Pyott to its Board of Directors - VisionMonday.com
Does Adding Ophthalmology Veteran David Pyott to the Board Change The Bull Case For Tarsus (TARS)? - Yahoo Finance
A Look At Tarsus Pharmaceuticals (TARS) Valuation After Adding Former Allergan CEO David Pyott To Its Board - Yahoo Finance
Former Allergan CEO David Pyott joins Tarsus Pharmaceuticals board By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader - The National Law Review
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors - BioSpace
Tarsus Pharmaceuticals (TARS) Welcomes Former Allergan CEO to Bo - GuruFocus
Tarsus Pharmaceuticals Adds Industry Veteran to Board - TipRanks
Former Allergan CEO David Pyott joins Tarsus Pharmaceuticals board - Investing.com
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):